ArticleBMJ open2025

Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol.

Ann-Sofie Backman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.